Endothelial nitric oxide synthetase, methylenetetrahydrofolate reductase polymorphisms, and cardiovascular complications in Tunisian patients with nondiabetic renal disease

Clinical Biochemistry

Volumn 42, Issue 10-11, 2009, Pages 958-964

  Kerkeni, Mohsen ^a   Letaief, Ahmed ^b   Achour, Abdellatif ^b   Miled, Abdelhedi ^c   Trivin, Francois ^d   Maaroufi, Khira ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d UNIVERSITÉ DE TOURS   (France)

Author keywords

Cardiovascular disease; eNOS gene; MTHFR gene; Polymorphism; Severity of renal disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENOMIC DNA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; TUNISIA;

AFRICAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MULTIVARIATE ANALYSIS; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; TUNISIA;

EID: 67349267674     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.04.005     Document Type: Article

References (51)

1. Abderrahim E., Zouaghi K., Hedri H., et al. Renal replacement therapy for diabetic end-stage renal disease. Experience of a Tunisian hospital centre. Diabetes Metab. 27 (2001) 584-590
2. Ben Maïz H., Abderrahim E., Ben Moussa F., Goucha R., and Karoui C. Epidemiology of glomerular diseases in Tunisian from 1975 to 2005. Influence of changes in healthcare and society. Bull. Acad. Natl. Med. 190 (2006) 403-416
3. Counil E., Cherni N., Hkarrat M., Achour A., and Trimech H. Trends of incidence dialysis patients in Tunisia between 1992 and 2001. Am. J. Kidney Dis. 51 (2008) 463-470
4. Nordfors L., Stenvinkel P., Marchlewska A., et al. Molecular genetics in renal medicine: what can we hope to achieve?. Nephrol. Dial. Transplant. 17 (2002) 5-11
5. Zate R., and De Nucci G. Effect of acute nitric oxide inhibition on rat glomerular microcirculation. Am. J. Physiol. 261 (1991) 360-363
6. Tolins J.P., Palmer R.M.J., Moncada S., and Raij L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am. J. Physiol. 258 (1990) 655-662
7. Tesauro M., Thompson W.C., Rogliani P., Qi L., Chaudhary P.P., and Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2832-2835
8. Wang Y., Kikuchi S., Suzuki H., Nagase S., and Koyama A. Endothelial nitric oxide synthase gene polymorphism in introns 4 affects the progression of renal failure in non-diabetic renal diseases. Nephrol. Dial. Transplant. 14 (1999) 2898-2902
9. Ykoyama K., Tsukada T., Matsuoka H., Hara S., Yamada A., and Kawaguchi Y. High accumulation of endothelial nitric oxide synthase (ecNOS): a gene polymorphism in patients with end-stage renal disease. Nephron 79 (1998) 360-361
10. Miyamoto Y., Salto Y., Kajiyama N., et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32 (1998) 3-8
11. Shin Shin Y., Hong Baek S., Yuk Chang K., et al. Relation between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res. Clin. Pract. 65 (2004) 257-265
12. Noiri E., Satoh H., Taguchi J.I., et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 40 (2002) 535-540
13. Nagase S., Suzuki H., Wang Y., et al. Association of ecNOS gene polymorphisms with end stage renal diseases. Mol. Cell. Biochem. 244 (2003) 113-118
14. Wrone E.M., Zehnder J.L., Hornberger J.M., McCann L.M., Coplon N.S., and Fortmann S.P. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int. 60 (2001) 1106-1113
15. Vychytil A., Fodinger M., Wolfl G., et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int. 53 (1998) 1775-1782
16. Hingorani A.D., Liang C.F., Fatibene J., et al. A common variant of the endothelial nitric oxide synthase (Glu298Asp) is a major risk for coronary artery disease in the UK. Circulation 100 (1999) 1515-1520
17. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., Schouten E.G., and MTHFR studies collaboration group. MTHFR 677T→T polymorphism and risk of coronary heart diseases: a meta-analysis. JAMA 288 (2002) 2023-2031
18. Kerkeni M., Addad F., Chauffert M., et al. Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease. Clin. Chem. 52 (2006) 53-58
19. Kerkeni M., Addad F., Chauffert M., et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann. Clin. Biochem. 43 (2006) 1-7
20. Vallet-Colom I., Levy-Marchal C., Zarrouk D., et al. HLA-DQ B1 codon 57 and genetic susceptibility to type I (insulin-dependent) diabetes mellitus in French children. Diabetogia 33 (1990) 174-176
21. Frosst P., Blom H.J., Milos R., et al. A candidate genetic for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10 (1995) 111-113
22. Weisberg I., Tran P., Christensen B., Sibani S., and Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64 (1998) 169-172
23. Buchmayer H., Fodinger M., Heiz G., et al. Association of two polymorphisms in MTHFR with total homocysteine plasma level in dialysis patients and healthy individuals. J. Am. Soc. Nephrol. (2000) abstract A1357 PS
24. Födinger M., Buchmayer H., Heinz G., et al. Effect of MTHFR 1298A→C and MTHFR 677C→T genotypes on total homocysteine, folate and vitamin B (12) plasma concentration in kidney graft recipients. J. Am. Soc. Nephrol. 11 (2000) 1918-1925
25. Zanchi A., Moczulski D.K., Hanna L.S., Wantman M., Warram J.H., and Krolewski A.S. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. (2000) 405-413
26. Suzuki H., Nagase S., Kikuchi S., Wang Y., and Koyama A. Association of a missense Glu298Asp mutation of the endothelial nitric oxide gene with end stage renal disease. Clin. Chem. 46 (2000) 1858-1860
27. Zintzaras E., Uhlig K., Koukoulis G.N., Papathanasiou A.A., and Stefanidis I. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor diabetic nephropathy: a meta-analysis. J. Hum. Genet. 52 (2007) 881-890
28. Mtiraoui N., Ezzidi I., Chaieb M., et al. MTHFR C677T and A1298C gene polymorphism and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabets Res. Clin. Pract. 75 (2007) 99-106
29. Asakimori Y., Yorioka N., Tanaka J., et al. Association between eNOS gene polymorphism and cardiovascular events in nondiabetic hemodialysis patients: a prospective study. Am. J. Kidney Dis. 44 (2004) 112-120
30. Kone B.C. Nitric oxide synthesis in the kidney: isoforms, biosynthesis, and function in health. Semin. Nephrol. 24 (2004) 299-315
31. Wever R., Boer P., Hijmering M., et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1168-1172
32. Schmid R.J., and Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 58 (2000) 1261-1266
33. Erdely A., Wagner L., Muller V., Szabo A., and Baylis C. Protection of Wister Furth rat from chronic renal disease is associated with maintained renal nitric oxide synthase. J. Am. Soc. Nephrol. 14 (2003) 2526-2533
34. Gschwend S., Buikema H., Navis G., Henning R., De Zeeuw D., and van Dokkum R. Endothelial dilatory function predicts individual susceptibility to renal damage in 5/6 nephrectomized rat. J. Am. Soc. Nephrol. 13 (2002) 2909-2915
35. Baylis C., Mitruka B., and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90 (1992) 278-281
36. Bibiero M.O., Antunes E., deNucci G., Lovisolo S.M., and Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20 (1992) 298-303
37. Zatz R., and Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 32 (1998) 958-964
38. Forbes M.S., Thornhill B.A., Park M.H., and Chevalier R.L. Lack of endothelial nitric oxide synthase leads to progressive focal renal injury. Am. J. Pathol. 170 (2007) 87-99
39. O'Riordan E., Mendelev N., Patschan, et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) 285-294
40. Domenici F.A., Vannucchi M.T., Simões-Ambrósio L.M., and Vannucchi H. Hyperhomocysteinemia and polymorphisms of the methylenetetrahydrofolate gene in hemodialysis and peritoneal dialysis patients. Mol. Nutr. Food Res. 51 (2007) 1430-1436
41. Bostom A.G., Gohh R.Y., Bausserman L., et al. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with normal serum creatinine. J. Am. Soc. Nephrol. 10 (1999) 164-166
42. Brattström L., and Wilcken D.E. Homocysteine and cardiovascular disease: cause or effect?. Am. J. Clin. Nutr. 72 (2000) 315-323
43. Guttormsen A.B., Ueland P.M., Svarstad E., and Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int. 52 (1997) 495-502
44. Födinger M., Mannhalter C., Wölfl C., et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int. 52 (1997) 517-523
45. Bostom A.G., Shemin D., Lapane K.L., et al. Folate status is the major determinant of fasting plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123 (1996) 193-202
46. Kimura H., Gejyo F., Suzuki S., and Miyazaki R. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. J. Am. Soc. Nephrol. 11 (2000) 885-893
47. Suliman M., Qureshi A.R., Barany P., et al. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int. 57 (2000) 1727-1735
48. Aucella F., Margaglione M., Grandone E., et al. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. Nephrol. Dial. Transplant. 20 (2005) 382-386
49. Fisher P.A., Dominguez G.N., Cunberti L.A., et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved?. J. Am. Soc. Nephrol. 14 (2003) 653-660
50. Stranger O., and Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin. Chem. Lab. Med. 41 (2003) 1444-1454
51. Tang F.Y., Lui F.Y., and Xie X.W. Association of angiotensin-converting enzyme and endothelial nitric synthase gene polymorphisms with vascular disease in ERSD patients in a Chinese population. Mol. Cell. Biochem. 319 (2008) 33-39